IDO2 and neoplasm: As previously discussed, lymphodepletion with chemotherapy prior to CART infusion improves T-cell persistence and cytotoxic activity (186) by killing immunosuppressive Tregs and MDSCs, eliminating homeostatic cytokine sinks (187), and modulating tumor IDO (indoleamine 2,3-dioxygenase) (188).